FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887836698> ?p ?o ?g. }

• W2887836698 abstract "The present study, administration of novel ER-β agonist at dose of 10mg/kg ameliorated the ischemic damage induced by middle cerebral artery occlusion.However, evidence of a role for ER-β in mediating endogenous E2 neuroprotection against cerebral ischemia is currently lacking, as E2 is fully capable of exerting neuroprotection against cerebral ischemia in ER-β knockout mice (Merchenthaler et al.,2005). Nevertheless,there is evidence that ER-β may have a role in basal neuronal survival, as it has been reported that there is substantial neuronal loss in the brains of ER-β knockout mice at 2 years of age ascompared to wild type mice (Wang et al., 2001). Being E2 protective there NCE can be notedon agonist. Several studies have shown that synthetic SERMs, such as tamoxifen, raloxifene or bazedoxifene and natural SERMs, like genistein (Azcoitia et al., 2006), are neuroprotective invitro and in vivo. Previous reports suggests that both ERα and ERβ regulated pro inflammatory cytokine and chemokine production through E -dependent and E -independentmechanisms (Brown et al., 2010). Estradiol and three ERβ-selective compounds, ERB-041,WAY-202196, and WAY-214156, repressed the expression of these inflammatory genes TNF-α, IL-6, and CSF2 by recruiting the coactivator, SRC-2 has been proved. Estrogenreceptors and IGF-I receptors cooperate in neuroprotection in animal models of hippocampalneurodegeneration, Parkinson’s disease and global cerebral ischemia (Azcoitia et al., 1999;Quesada and Micevych, 2004; Garcia-Segura et al., 2006; Mendez et al., 2006). In addition, IGF-I receptor and estrogen receptor activation synergistically increase the activity of the kinase Akt and coordinately regulate protection from neurotoxicity downstream of Akt whichfurther activates glycogen synthase kinase 3β (GSK3β) (Cardona- Gomez et al., 2004).Administration of novel ER-β agonist to MCAo occluded rats did not alter the GSK3β/Aktpathway. In a recent study that the silencing of hippocampal ER β - increased inflammasome activation; whereas periodic ER- β agonist treatment reduced the activation of the inflammasome, consistent with decreased processing of IL- 1β(de Rivero Vaccari et al.,2016). Estrogens can also inhibit expression of pro-inflammatory cytokines such as IL-1βand TNF-α in primary astrocytes following LPS exposure (Lewis et al., 2008). In this study,novel ER β agonist down regulated the brain IL-1β and TNF-α level suggesting their role incontrolling neuro inflammation in cerebral ischemic condition. Caspase-3, the final executioner of apoptotic cell death mechanism, is a substrate of calpainand it becomes active following degradation by calpain, and therefore, up regulated calpain is expected to activate caspase-3 in the injured tissue (Gao and Dou.,2000). In our study treatment of novel ER β agonist reduced the caspase 3 activity in MCAo rats. The selective ERα agonist (propylpyrazole triol, PPT) and ERβ agonist (diarylpropionitrile; DPN) are supposed to show similar neuroprotective actions in culture studies. But a previous report showed higher neuroprotective potential of the ERα agonist PPT than the ERβ agonist DPN (Behl et al., 1995). Some other investigations showed that both PPT and DPN canprovide neuroprotection against glutamate toxicity by increasing the expression of the anti-apoptotic Bcl-2 protein and also modulating the stress kinase signaling pathways (Zhao et al., 2007). In this study, anti-apoptotic protein bcl2 level were increased and proapoptotic protein levels were reduced on administration of novel ER β agonist to MCAo rats. SUMMARY & CONCLUSION: The objective of the study is to asses the behavioural functions of ER-β stimulation in cerebral ischemic condition using novel NCEs.  To evaluate the mechanism of neuroprotective activity of ER-β agonist in cerebral ischemia by exploring the anti-inflammatory pathways.  MCAo was induced by occluding middle cerebral artery under anesthetic condtions and thebehavaioural parameters were studied after 24 hrs and on 7th day.  ER-β agonist CMU, CUE (10mg/kg) has been assessed for their neuroprotective action. The behavioural parameters include measurement of neurogical deficit through grip strengthmeasurement, anxiety beahviour in open feild and elevated plus maze tests. Inducement of MCAo in rats have shown decreased locomtor activity, exploratory, rearing,grooming behaviours, indicates inducement of cerebral ischemia have resulted in anxiogenic behaviour. Post ischemic administration of CMU, CUE (10mg/kg) significantly attenuated the behavioural in MCAo rats as observed by increased locomotor activity, exploratory &grooming behavious, grip strength.  Post ischemic administration of CMU, CUE (10mg/kg) significantly reduced the IL-1β, TNF-α and caspase activity. CUE (10mg/kg) significantly reduced the pro apoptotic Bax & anti apoptotic Bcl2 levels. Novel ER-β agonist has shown neuroprotective effect by downregulating neuro inflammation and attenuating apoptotic pathway." @default.
• W2887836698 created "2018-08-22" @default.
• W2887836698 creator A5088754568 @default.
• W2887836698 date "2017-10-01" @default.
• W2887836698 modified "2023-09-24" @default.
• W2887836698 title "Effect of Novel ERβ Agonist in Controlling Neuroinflammation and Apoptosis in Cerebral Ischemia in Rat Model" @default.
• W2887836698 hasPublicationYear "2017" @default.
• W2887836698 type Work @default.
• W2887836698 sameAs 2887836698 @default.
• W2887836698 citedByCount "0" @default.
• W2887836698 crossrefType "dissertation" @default.
• W2887836698 hasAuthorship W2887836698A5088754568 @default.
• W2887836698 hasConcept C121608353 @default.
• W2887836698 hasConcept C126322002 @default.
• W2887836698 hasConcept C134018914 @default.
• W2887836698 hasConcept C166471694 @default.
• W2887836698 hasConcept C169760540 @default.
• W2887836698 hasConcept C170493617 @default.
• W2887836698 hasConcept C182704531 @default.
• W2887836698 hasConcept C25498285 @default.
• W2887836698 hasConcept C2776914184 @default.
• W2887836698 hasConcept C2777944059 @default.
• W2887836698 hasConcept C2778938600 @default.
• W2887836698 hasConcept C2779889926 @default.
• W2887836698 hasConcept C530470458 @default.
• W2887836698 hasConcept C541997718 @default.
• W2887836698 hasConcept C71924100 @default.
• W2887836698 hasConcept C84606932 @default.
• W2887836698 hasConcept C86803240 @default.
• W2887836698 hasConcept C87753298 @default.
• W2887836698 hasConcept C98274493 @default.
• W2887836698 hasConceptScore W2887836698C121608353 @default.
• W2887836698 hasConceptScore W2887836698C126322002 @default.
• W2887836698 hasConceptScore W2887836698C134018914 @default.
• W2887836698 hasConceptScore W2887836698C166471694 @default.
• W2887836698 hasConceptScore W2887836698C169760540 @default.
• W2887836698 hasConceptScore W2887836698C170493617 @default.
• W2887836698 hasConceptScore W2887836698C182704531 @default.
• W2887836698 hasConceptScore W2887836698C25498285 @default.
• W2887836698 hasConceptScore W2887836698C2776914184 @default.
• W2887836698 hasConceptScore W2887836698C2777944059 @default.
• W2887836698 hasConceptScore W2887836698C2778938600 @default.
• W2887836698 hasConceptScore W2887836698C2779889926 @default.
• W2887836698 hasConceptScore W2887836698C530470458 @default.
• W2887836698 hasConceptScore W2887836698C541997718 @default.
• W2887836698 hasConceptScore W2887836698C71924100 @default.
• W2887836698 hasConceptScore W2887836698C84606932 @default.
• W2887836698 hasConceptScore W2887836698C86803240 @default.
• W2887836698 hasConceptScore W2887836698C87753298 @default.
• W2887836698 hasConceptScore W2887836698C98274493 @default.
• W2887836698 hasLocation W28878366981 @default.
• W2887836698 hasOpenAccess W2887836698 @default.
• W2887836698 hasPrimaryLocation W28878366981 @default.
• W2887836698 hasRelatedWork W1799305440 @default.
• W2887836698 hasRelatedWork W2039226990 @default.
• W2887836698 hasRelatedWork W2047908986 @default.
• W2887836698 hasRelatedWork W2073092339 @default.
• W2887836698 hasRelatedWork W2297819692 @default.
• W2887836698 hasRelatedWork W2343827984 @default.
• W2887836698 hasRelatedWork W2530261665 @default.
• W2887836698 hasRelatedWork W2534351262 @default.
• W2887836698 hasRelatedWork W2610924537 @default.
• W2887836698 hasRelatedWork W2887369733 @default.
• W2887836698 hasRelatedWork W2927135929 @default.
• W2887836698 hasRelatedWork W2978466993 @default.
• W2887836698 hasRelatedWork W2982694967 @default.
• W2887836698 hasRelatedWork W3005529505 @default.
• W2887836698 hasRelatedWork W3127162110 @default.
• W2887836698 hasRelatedWork W3152612895 @default.
• W2887836698 hasRelatedWork W3202637203 @default.
• W2887836698 hasRelatedWork W3210328074 @default.
• W2887836698 hasRelatedWork W3213103088 @default.
• W2887836698 hasRelatedWork W767309710 @default.
• W2887836698 isParatext "false" @default.
• W2887836698 isRetracted "false" @default.
• W2887836698 magId "2887836698" @default.
• W2887836698 workType "dissertation" @default.